

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **LifeTech Scientific Corporation**

**先 健 科 技 公 司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1302)**

### **VOLUNTARY ANNOUNCEMENT CAPITAL INCREASE AND STRATEGIC INVESTMENT IN AFFECTOR MEDTECH (SUZHOU) LTD.**

This announcement is made by LifeTech Scientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide its shareholders and potential investors with information relating to the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 6 June 2025, the Group, through its wholly-owned subsidiary, Lifetech Scientific (Shenzhen) Co., Ltd. (“**Lifetech Shenzhen**”), entered into a series of agreements in relation to the proposed investment in Affector Medtech (Suzhou) Ltd. (“**Affector Medtech**”), a high-tech company established in the People’s Republic of China specializing in the field of electrophysiology and innovative medical devices (the “**Investment**”).

#### **Key Terms of the Investment**

##### *Investment Amount and Structure*

Lifetech Shenzhen has agreed to invest a total of RMB150 million in Affector Medtech in cash. The Investment will be made in stages, subject to the achievement of certain milestones as set out in the investment agreement, including the founders and core team of Affector Medtech entering into employment contracts, confidentiality agreements, and non-competition agreements satisfactory to Lifetech Shenzhen, as well as Affector Medtech obtaining China National Medical Products Administration (“**NMPA**”) registration certificates for certain specific products.

Part of the Investment will be used to increase the registered capital of Affector Medtech, while the remaining amount will be credited to capital reserve. After completion of all stages of Investment, Lifetech Shenzhen will be entitled to 30% of the equity interest in Affector Medtech, with 22.22% to be acquired immediately after the completion of the first stage. It is expected that the Investment will not result in Affector Medtech becoming a subsidiary of the Company.

#### *Governance and Investor Protection*

Following the Investment, Lifetech Shenzhen is entitled to nominate directors to the board of Affector Medtech and participate in certain decision-making in the management of Affector Medtech.

The investment agreements also include customary investor protection provisions, including anti-dilution rights, pre-emptive rights, co-sale rights and put options (repurchase rights) in the event of certain trigger events, as well as information and audit rights for Lifetech Shenzhen and other key investors.

#### *Strategic Cooperation*

In connection with the Investment, Lifetech Shenzhen and Affector Medtech have entered into a strategic cooperation agreement to jointly promote the research, development, and commercialization of innovative cardiac intervention imaging platform products. Both parties will also explore the joint development of products or technologies, the establishment of a sales platform and other forms of business collaboration to leverage their respective strengths and resources.

The Group will have the exclusive priority cooperation rights and exclusive overseas distribution rights for Affector Medtech's electrophysiology-related products, including but not limited to StarTrek 3D Mapping System, Halocraft Diagnostic Catheter, Pentacraft HD Diagnostic Catheter, Axpert CF Irrigation RF Ablation Catheter, SinusAblate RF Ablation System, Alphatrion NanoPulse Field Ablation System, HaloPulse PFA Catheter, and other products.

### **INFORMATION ON AFFECTOR MEDTECH**

Affector Medtech was registered and established in February 2021. It is an innovative high-end medical device enterprise that integrates independent research and development, design, production and sales. Affector Medtech has a strong research and development team dedicated to independent innovation, aiming to become a platform-type company providing integrated solutions encompassing cardiac electrophysiological 3D mapping, pulsed fields ablation and radiofrequency ablation, and various catheter consumables. In May 2025, the StarTrek® 3D Mapping System independently developed by Affector Medtech obtained official registration approval from the NMPA. As of the date hereof, to the best of the Company's

knowledge, information and belief, none of Affector Medtech and its ultimate beneficial owners is a connected person of the Company under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

## **REASONS FOR AND BENEFITS OF THE INVESTMENT**

The Company believes that the strategic investment in Affector Medtech will enable the Group to further expand its presence in the high-growth medical device sector, enhance its technological capabilities, and create synergies with its existing business. The collaboration is expected to accelerate the development and commercialization of innovative products, strengthen the Group’s competitive position, and generate long-term value for shareholders.

The Company intends to fund the Investment by the Group’s internal financial resources.

The Investment will not constitute a notifiable transaction of the Company under Chapter 14 of the Listing Rules or a connected transaction of the Company under Chapter 14A of the Listing Rules.

By order of the Board  
**LifeTech Scientific Corporation**  
**XIE Yuehui**  
*Executive Director, Chairman  
and Chief Executive Officer*

Hong Kong, 9 June 2025

*As at the date of this announcement, the Board comprises Mr. XIE Yuehui, Mr. LIU Jianxiong and Ms. RUAN Xingmei being executive Directors; Mr. JIANG Feng being non-executive Director; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.*